← brief for 2026-08-13 · Slowing decline
Empagliflozin
Key takeaways
This trial showed empagliflozin reduced kidney decline in patients with type 2 diabetes and kidney disease. The drug was safe for 3 years of use.
Who did this work
CDA-AMC
Source
Paper · OpenAlex, CKD works · 2026-08-11
https://doi.org/10.51731/cjht.2026.1499